122 related articles for article (PubMed ID: 36511014)
1. Recurrent squamous cell carcinoma of the skin treated with immunotherapy.
Srinivasa BJ; Sridhar PS; Lalkota BP; Tsikai N; Niyati PS; Shah M; Anuradha S; Roopesh R; Ramaswamy V; Naik R; Ajaikumar BS
J Cancer Res Ther; 2022 Dec; 18(Supplement):S495-S497. PubMed ID: 36511014
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for recurrent/metastatic head and neck cancers.
Karabajakian A; Toussaint P; Neidhardt EM; Paulus V; Saintigny P; Fayette J
Anticancer Drugs; 2017 Apr; 28(4):357-361. PubMed ID: 28166090
[TBL] [Abstract][Full Text] [Related]
3. Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report.
Hsieh ML; Besch BM; Peterson JEG; Henson C
J Med Case Rep; 2022 Oct; 16(1):364. PubMed ID: 36195921
[TBL] [Abstract][Full Text] [Related]
4. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
5. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
Day F; Kumar M; Fenton L; Gedye C
J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
Martínez P; Del Campo JM
Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
[TBL] [Abstract][Full Text] [Related]
7. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges.
Ansary TM; Hossain MDR; Komine M; Ohtsuki M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955666
[TBL] [Abstract][Full Text] [Related]
10. Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report.
Wu Q; Zhang S; Hua X; Yu H; Zhong Y
Ann Palliat Med; 2021 Jun; 10(6):6968-6973. PubMed ID: 33183019
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
Tellez-Bernal E; Belehradek M; Recondo G; Cvitkovic E; Leridant AM; Vericel R; Armand JP
Am J Clin Oncol; 1990 Oct; 13(5):452-4. PubMed ID: 1699403
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
13. Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy.
Furkert C; Martin R; Sharma A; Rivalland G
World J Surg Oncol; 2023 Sep; 21(1):291. PubMed ID: 37715254
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
Hughes BGM; Munoz-Couselo E; Mortier L; Bratland Å; Gutzmer R; Roshdy O; González Mendoza R; Schachter J; Arance A; Grange F; Meyer N; Joshi A; Billan S; Zhang P; Gumuscu B; Swaby RF; Grob JJ
Ann Oncol; 2021 Oct; 32(10):1276-1285. PubMed ID: 34293460
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
17. A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab.
Yamashita G; Okamoto I; Shimizu A; Tokashiki K; Okada T; Sato H; Tsukahara K
In Vivo; 2022; 36(2):1047-1051. PubMed ID: 35241570
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
19. Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report.
Chen C; Sun P; Long J
Front Immunol; 2022; 13():941092. PubMed ID: 35983052
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
